GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aurobindo Pharma Ltd (NSE:AUROPHARMA) » Definitions » Price-to-Owner-Earnings

Aurobindo Pharma (NSE:AUROPHARMA) Price-to-Owner-Earnings : 90.52 (As of May. 15, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Aurobindo Pharma Price-to-Owner-Earnings?

As of today (2024-05-15), Aurobindo Pharma's share price is ₹1168.60. Aurobindo Pharma's Owner Earnings per Share (TTM) ended in Mar. 2023 was ₹12.91. It's Price-to-Owner-Earnings for today is 90.52.


The historical rank and industry rank for Aurobindo Pharma's Price-to-Owner-Earnings or its related term are showing as below:

NSE:AUROPHARMA' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 6.76   Med: 37.87   Max: 208.34
Current: 87.33

During the past 13 years, the highest Price-to-Owner-Earnings of Aurobindo Pharma was 208.34. The lowest was 6.76. And the median was 37.87.


NSE:AUROPHARMA's Price-to-Owner-Earnings is ranked worse than
85.44% of 419 companies
in the Drug Manufacturers industry
Industry Median: 28.45 vs NSE:AUROPHARMA: 87.33

As of today (2024-05-15), Aurobindo Pharma's share price is ₹1168.60. Aurobindo Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₹47.25. Therefore, Aurobindo Pharma's PE Ratio for today is 24.73.

As of today (2024-05-15), Aurobindo Pharma's share price is ₹1168.60. Aurobindo Pharma's EPS without NRI for the trailing twelve months (TTM) ended in was ₹48.21. Therefore, Aurobindo Pharma's PE Ratio without NRI for today is 24.24.

During the past 13 years, Aurobindo Pharma's highest PE Ratio without NRI was 28.81. The lowest was 7.71. And the median was 16.70.


Aurobindo Pharma Price-to-Owner-Earnings Historical Data

The historical data trend for Aurobindo Pharma's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurobindo Pharma Price-to-Owner-Earnings Chart

Aurobindo Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 73.68 7.31 11.48 9.27 40.13

Aurobindo Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 40.13 - - -

Competitive Comparison of Aurobindo Pharma's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Aurobindo Pharma's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aurobindo Pharma's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aurobindo Pharma's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Aurobindo Pharma's Price-to-Owner-Earnings falls into.



Aurobindo Pharma Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Aurobindo Pharma's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1168.60/12.91
=90.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aurobindo Pharma  (NSE:AUROPHARMA) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Aurobindo Pharma Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Aurobindo Pharma's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Aurobindo Pharma (NSE:AUROPHARMA) Business Description

Traded in Other Exchanges
Address
Plot No. 1, Survey No. 83/1, Galaxy, Floors: 22-24, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad, TG, IND, 500 032
Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. The company's product portfolio spans a variety of therapeutic areas. The vast majority of the company's sales are generated in the United States, followed by Europe. Most of Aurobindo's sales are derived from its formulations business, with the rest stemming from its active pharmaceutical ingredient operations. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Aurobindo Pharma (NSE:AUROPHARMA) Headlines

No Headlines